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Gastrointestinal neuropathies in patients with diabetes represent vital aspects of the chronic course of the disease. They may 
include oesophageal dysmotility, gastroparesis, small 
bowel dysmotility or diarrhoea and fecal incontinence.1 
More precisely, reduced gastric emptying (GE) has been 
frequently reported in diabetic patients having gastro- 
intestinal autonomic neuropathy.2 Delayed GE was first 
reported by Boas in 1925, which was subsequently termed 
gastroparesis diabeticorum by Kassender in 1958.3,4 A 
symptom entailing contractile, functional, sensory and 
electrical dysfunction of the stomach was then identified 
and described as diabetic gastroparesis (DG).5 This can 
be perceived as chronic delayed GE associated with 
nausea, vomiting, postprandial fullness, weight loss, 
anorexia and abdominal pain without evidence of 
mechanical obstruction. Furthermore, DG patients 
usually have poor quality of life and poor glycaemic 
control; in addition, the disease imposes a significant 
financial burden on healthcare systems.6
The prevalence of DG varies in the literature; in 
general, the risk of gastroparesis is higher in patients 
with type 1 diabetes mellitus (T1DM) compared to 
type 2 diabetes mellitus (T2DM). DG disease prevalence 
in T1DM was found to be 4.8% based on diabetes 
registries while tertiary medical centres have reported 
a prevalence of up to 64%.7–9 In T2DM, DG is reported 
in 10.8–30% of patients.10,11 Gender differences were 
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abstract: Pharmacological interventions of diabetic gastroparesis (DG) constitute an essential element of a 
patient’s management. This article aimed to systematically review the available pharmacological approaches of 
DG, including their efficacy and safety. A total of 24 randomised clinical trials (RCTs) that investigated the efficacy 
and/or safety of medications targeting DG symptoms were identified using several online databases. Their results 
revealed that metoclopramide was the only approved drug for accelerating gastric emptying and improving disease 
symptoms. However, this medication may have several adverse effects on the cardiovascular and nervous systems, 
which might be resolved with a new intranasal preparation. Acceptable alternatives are oral domperidone for 
patients without cardiovascular risk factors or intravenous erythromycin for hospitalised patients. Preliminary 
data indicated that relamorelin and prucalopride are novel candidates that have proven to be effective and safe. 
Future RCTs should be conducted based on unified guidelines using universal diagnostic modalities to reveal 
reliable and comprehensive outcomes.
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َكري عن�رسا اأ�صا�صيا لعالج املري�ض. تهدف هذه املقالة اإىل مراجعة منتظمة للُنُهج  امللخ�ص: ت�صكل التدخالت الدوائية يف َخَزل املعدة ال�صُّ
َكري، مبا يف ذلك فعاليتها و�صالمتها. مت حتديد ما جمموعه 24 جتربة �رسيرية ع�صوائية والتي  الدوائية املتوافرة لعالج َخَزل املعدة ال�صُّ
َكري با�صتخدام العديد من قواعد البيانات عرب النرتنت.  مت التحقق من فعالية و�صالمة الأدوية التي ت�صتهدف اأعرا�ض َخَزل املعدة ال�صُّ
اأظهرت نتائج هذه التجارب اأن امليتوكلوبراميد كان الدواء الوحيد املعتمد لت�رسيع التفريغ امَلِعِدي وحت�صني اأعرا�ض املر�ض. ومع ذلك ، قد 
يكون لهذا الدواء العديد من الآثار اجلانبية على اجلهاز القلبي الوعائي واجلهاز الع�صبي، والتي ميكن التغلب عليها عن طريق م�صتح�رس 
اأو  جديد ي�صتخدم عرب الأنف. البدائل املقبولة هما الدومبرييدون عن طريق الفم للمر�صى الذين لي�ض لديهم عوامل خطر قلبية وعائية 
الإريرثومي�صني عن طريق احلقن الوريدي للمر�صى املنومني يف امل�صت�صفى. اأ�صارت البيانات الأولية اإىل اأن الريالموريلني والربوكالوبريد 
اإجراء جتارب �رسيرية ع�صوائية م�صتقبلية بناًء على  هي من الأدوية املر�صحة اجلديدة التي ثبتت فعاليتها و�صالمة ا�صتعمالها. ينبغي 
مبادئ توجيهية موحدة با�صتخدام طرائق ت�صخي�صية عامة للك�صف عن نتائج موثوقة و�صاملة.
َكِري؛ جتربة ع�صوائية ُمراقبة؛ ميتوكلوبراميد؛ دومبرييدون؛ ريالموريلني. َكِري؛ م�صاعفات ال�صُّ َكري؛ داء ال�صُّ الكلمات املفتاحية: َخَزل املعدة ال�صُّ
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observed in several publications where females had 
higher prevalence rates than males.8,10,12 Poorly-
controlled diabetes, higher glycosylated haemoglobin 
(HbA1c), long duration of diabetes and the presence 
of comorbidities have been consistently reported as 
independent risk factors of DG.8,10 Similarly, in an 
epidemiological study involving 8,657 individuals in 
Australia, patients with poor glycaemic control had 
increased prevalence of upper and lower gastro- 
intestinal symptoms.12 Additionally, the probability of 
developing DG symptoms increased with advanced 
age, with a mean age of onset at approximately 34 years.5
The diagnosis of DG may remain elusive until the 
development of complications. To avoid this delay, a 
precise medical history of the timing of symptoms (i.e. 
vomiting and satiety) in relation to meals, diet history, 
symptom progression and diabetes control should 
be carefully assessed. Severity of DG symptoms is 
evaluated using the Gastroparesis Cardinal Symptom 
Index (GCSI), which can be utilised to rate changes in 
symptoms in clinical studies either by the patient or the 
physician on a scale ranging from zero (no symptoms) 
to six (very severe symptoms).13 Furthermore, gastric 
obstruction can be excluded using abdominal radiography, 
computed tomography and magnetic resonance imaging 
scans. Consequently, a DG diagnosis is confirmed by 
means of three main diagnostic tests. The first method 
is gastric emptying scintigraphy (GES), which is a non-
invasive method employing a radio-labelled solid meal 
(mostly using 99mTc-sulfur) followed by scanning the 
stomach at one, two and four hours after the meal.14 
The second method is the stable isotope breath test 
(gastric emptying breath test [GEBT]). After ingestion 
of meals with 13C-labelled substrates, such as octanoic 
acid and Spirulina platensis, the isotope is absorbed 
in the small intestine and metabolised to 13carbon 
dioxide and exhaled through the lungs. Finally, a recent 
diagnostic modality is a swallowed wireless motility 
capsule wherein a specialised sensor is used to measure 
pressure, temperature and pH.15
GE in patients with DG is challenging in terms of 
treatment. This is particularly evident because optimum 
glycaemic control should be achieved in poorly-
controlled diabetic patients. Dietary modifications, 
such as replacing solid food with a soft and liquid 
diet, are required. Several pharmacologic options are 
available although the efficacy and safety of these 
medications vary. Usually, patients with mild to moderate 
symptoms are managed by prokinetics and antiemetics. 
However, disease burden in patients experiencing 
severe symptoms is difficult to manage. Therefore, it is 
necessary to determine the most appropriate therapeutic 
options bearing in mind the prevention of potential 
gastrointestinal complications in DG patients including 
gastroesophageal reflux disease, bacterial and fungal 
infections of the gastrointestinal tract and intestinal 
dysmotility. In this context, this article aimed to 
systematically review the available approaches for the 
pharmacotherapy of DG, including their efficacy and 
safety and emphasising their roles in patients with 
different disease severities.
Methods
Based on the guidelines provided by the Preferred 
Reporting Items for Systematic reviews and Meta-
analyses statement, this systematic review was cond- 
ucted on investigated medications of diabetic patients 
with DG.16 In the context of DG, a medication’s efficacy 
targets the severity of symptoms and/or GE while 
safety deals with the reported adverse events (AEs) in 
the groups under investigation.
MEDLINE® (National Library of Medicine, 
Bethesda, Maryland, USA), EMBASE (Elsevier, 
Amsterdam, Netherlands), Cochrane Library (Wiley, 
Hoboken, New Jersey, USA) and Google Scholar 
(Google LLC, Menlo Park, California, USA) databases 
were used to search for randomised clinical trials (RCTs) 
that assessed the efficacy and/or safety of medications 
used for the management of DG. Although the last 
search was performed until April 2019, there was no 
time limit set for the included trials. The search strategy 
used specific keywords based on a Patient/Problem, 
Intervention, Comparison and Outcome strategy, 
utilising relevant subject headings and Boolean Operators. 
These databases were searched with the terms “diabetes” 
or “diabetic”, “gastroparesis” or a combination of the 
two, “prokinetics” or “prokinetic”, “metoclopramide” 
or “domperidone” or “erythromycin” or “cisapride” 
or “bethanecol” or “tegaserod”, “Motilin agonist” 
or “ghrelin agonist” or “5-HT4 agonist” (5-hydroxy- 
tryptamine receptor 4) and “antiemetic” or “phenothiazine” 
or “serotonin 5-HT3 Receptor Antagonist” or “anti- 
histamine”. Only RCTs with the following charact- 
eristics were included in this review: (1) DG had to be 
diagnosed based on the exclusion of gastrointestinal 
obstruction; (2) studies should have allocated at least 
two groups for comparing the outcomes of a single 
medication versus placebo or another medication; (3) 
the allocated patients may be adults or children with 
T1DM or T2DM; (4) the study should be published in 
a peer-reviewed journal and written in English; (5) the 
primary outcomes of the RCT should include changes 
in the scores of the severity of symptoms (as indicated 
by the GCSI scale, visual analogue scores, etc.) in 
addition to changes in GE (assessed by ultrasound, 
GES, GEBT or the swallowed wireless motility capsule); 
(6) all changes should have been initially measured at 
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baseline and reassessed during the course of the study 
after the administration of medication(s); (7) the AEs 
should have been assessed in patients in accordance 
with the physical examination or patient self-reported 
data; and (8) changes in GE as retrieved from GEBT 
may be reported as gastric half-emptying time (T½). 
Studies recruiting a population or subpopulation of 
healthy individuals or presenting comorbidities with 
serious conditions rather than diabetes were excluded. 
Additionally, studies were ineligible if they were non-
randomised prospective investigations, retrospective 
studies, narrative reviews, systematic reviews and meta- 
analyses. 
Finally, a comprehensive search for on-going 
clinical trials for each medication in ClinicalTrials.gov 
(https://clinicaltrials.gov/) was performed. A medic- 
ation was considered novel when its relevant phase 2 
RCT was published in 2010 or later.
Two authors independently screened the titles 
and abstracts obtained by the database search process. 
Additionally, the reference lists of the identified RCTs 
were screened for additional eligible studies. The obtained 
publications were uploaded to EndNote, Version 
X7 (Clarivate Analytics, Philadelphia, USA) and all 
duplicate publications were omitted. Decisions regarding 
the included studies were approached via consensus 
and any disagreement was resolved via discussion. All 
data were extracted into a specifically-designed Excel 
spreadsheet, Version 2016 (Microsoft Inc., Redmond, 
Washington, USA), that included: 1) study data (name 
of the first author, year of publication, study design, 
study duration and country); 2) patients’ data (gender, 
total sample size, age, type of diabetes, glycaemic 
indicators [e.g. HbA1c] and baseline parameters used 
to confirm DG symptoms); 3) study groups and inter- 
ventions (medication(s) used and/or placebo, dosage 
and methods and duration of administration); 4) the 
efficacy of medication(s) (changes in severity scores 
and/or GE in relation to other groups and baseline values 
when appropriate); and 5) the safety of medication(s) 
(reported AEs following drug administration).
The methodological quality of the included RCTs 
was assessed using the Cochrane’s Risk of Bias Tool.17 
The domains assessed in each trial included perform- 
ance bias, selection bias, detection bias, attrition bias 
and other biases. The results of the assessment process 
were either reported as “low risk”, “high risk” or 
“unclear”. Trials were labelled “unclear” when no data 
were available in the RCT about the domain under 
investigation. All data were entered and graphically 
presented using RevMan, Version 5.3 (Cochrane, 
London, England). 
Results
A total of 854 publications were initially obtained in 
the specified databases by using the relevant keywords. 
Four studies were additionally identified from Google 
search (Google LLC). Following the removal of 18 
duplicate publications, the titles and abstracts of 840 
studies were screened and 809 were excluded. The 
full-text versions of the remaining 31 articles were 
thoroughly checked for eligibility. Nonetheless, seven 
articles were excluded due to the inclusion of healthy 
individuals, inclusion of patients with idiopathic 
gastroparesis, inclusion of patients with diabetes but 
without signs/symptoms of gastroparesis or a separate 
trial which included a population subset of an already 
included study.18–24 Finally, a total of 24 RCTs were 
included in this qualitative review [Figure 1].
A total of 2,309 patients, of which the majority 
(65.22%) were female, were included in all studies 
which were published between 1982 and 2017. Only 
one RCT recruited paediatric patients; adults were 
included in the remaining investigations.25 Studies 
were conducted in European countries, at multiple 
sites in Europe and the USA or only in the USA.25–33 
Patients were diagnosed with T1DM exclusively in 
nine studies,25,30,31,34–39 only T2DM in one study and 
both types in the remaining trials [Table 1].40
Figure 2 shows the summary of risk of bias 
assessment. Random sequence generation was generated 
by a computer software in eight trials and an Inter- 
active Voice Response System was used in four 
trials.27,29–33,38,40–44 Since the method of randomisation 
 
Figure 1: A flowchart of the search process used to 
identify randomised clinical trials investigating the 
efficacy and/or safety of medications targeting diabetic 
gastroparesis symptoms (N = 24).
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Table 1: Summary of the included randomised clinical trials investigating the efficacy and/or safety of medications targeting diabetic gastroparesis symptoms21,25–45,59,66
Author 




Country Gender Age in 
years








12 months Germany 5 14 19 56–72 HbA1c: 
7.1–8.2%
• GEBT T½ >170 min
Camilleri 
et al.42 (2017)
3 months USA 148 245 393 20–76 HbA1c: 
5.2–11.0%
• DG Symptom Severity daily e-diaries (to report 
vomiting frequency, GE and other symptom scores)
Desautels et 
al.59 (1995)
NA USA 10 0 10 26–70 HbA1c: 
6.7–12.9%
• History of previous GES
Ejskjaer 
et al.28 (2009)
10 months Denmark 5 5 10 46–56 HbA1c: 
9.5 ± 2.2 % 
• GCSI scores: 3.0 ± 0.9 (moderate to severe 
DG); ≥29% retention 4 hours following a 
radio-labelled solid meal. 
• Gastric T½ above the normal limits for both 
breath test and scintigraphy
Ejskjaer 
et al.29 (2010)
17 months Denmark 25 51 76 18–80 HbA1c: 
6.6–10.9%
• GCSI scores: 3.4-4 (moderate to severe DG) 
• Gastric T½ above the normal limits for both 
breath test and scintigraphy
Ejskjaer 
et al.32 (2013)
13 months 18 centres 
in different 
countries
32 60 92 20–70 HbA1c: 
6.5–10.2%
• GCSI-DD score: 3.3 ± 0.8 (moderate-to-severe DG) 
• GMBT T½ ≥150 min
Erbas 
et al.26 (1993)
9 weeks Turkey 4 9 13 19–68 Self-reported treatment 
by an oral diabetic agent 
and/or insulin
• A specific questionnaire for DG symptoms (patients 
were graded as experiencing severe symptoms) 




8 weeks Italy 14 14 28 6–16.9 Insulin dependence for a 













14 months USA 67 137 204 18–75 HbA1c: ≤11% • GCSI-DD score ≥2.6 
• Gastric T½ ≥79 min by 13C-GEBT
McCallum 
et al.35 (1983)
3 weeks USA 16 28 44 21–67 Insulin dependence for 
12.6 years




12 weeks USA 139 253 392 18–70 HbA1c: 
7.7 ± 1.7%
• Composite TSS score: 2.38 ± 0.69
McCallum 
et al.43 (2013)
22 months USA 56 145 201 42–66 HbA1c: 
7.8 ± 1.5%
• GCSI score: 3.4 ± 0.7 (moderate to severe DG) 
• The Michigan Neuropathy Screening Instrument 
score: 5 ± 2.6 (mild neuropathy) 




N/A UK 5 5 10 36–63 HbA1c: 
≤11%
• Patients were recruited based on the presence of bloat 
plus two gastrointestinal symptoms as predictors of DG
Parkman 
et al.33 (2014)
6 weeks USA (in 6 
centres)
41 48 89 18–82 N/A • Mean TSS score range: 21.3–23.4 (indicating 
moderate to severe symptoms) 
• All symptoms were reported except nausea at baseline
Parkman 
et al.44 (2015)
4 weeks USA 83 202 285 18–75 Self-reported treat- 
ment by an oral diabetic 
agent and/or insulin
• GCSI-DD score: 2.74 ± 0.48
Patterson 
et al.37 (1999)
4 weeks USA 33 62 95 19–69 N/A • TSS scale
Ricci 
et al.36 (1985)
6 weeks USA 6 7 13 24–73 Insulin dependence for 
12.5 years




6 months USA 2 8 10 31–65 HbA1c: ≤11.3% • GCSI-DD score: 1.66 ± 0.38 
• Gastric T½: 4.9 ± 1.3 by 13C-GEBT 
• Baseline composite NVFP score: 1.73 ± 0.39
Shin 
et al.40 (2013)
3 months USA 0 10 10 36–60 HbA1c: 
7.2 ± 0.4%
• GCSI-DD score: 1.32 ± 0.21
Silvers 
et al.45 (1998)
4 weeks USA 66 142 208 19–76 N/A • TSS scale of five symptoms (≥8 out of 15, indicating 
moderate to severe DG)
Snape 
et al.34 (1982)
6 weeks USA 5 5 10 21–49 Insulin dependence for 
16.2 ± 2.4 years
• A specific questionnaire for DG symptoms 
• Objective documentation of delayed GE by 
   a radionuclide solid meal
N/A = not available; GCSI-DD = The Gastroparesis Cardinal Symptom Index-Daily Diary; GE = gastric emptying; 13C-GEBT = 13C-spirulina gastric emptying breath test; T½ = half-emptying time; HbA1C = glyco- 
sylated haemoglobin; DG = diabetic gastroparesis; min = minutes; GES = gastric emptying scintigraphy; GMBT = gastric motility breath test; TSS = total symptom score; NVFP = nausea, vomiting, fullness, and pain.
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was inexplicitly mentioned in the remaining RCTs, 
they were assessed as “unclear”. Participants’ allocation 
was concealed from the investigators in ten trials, 
while selection bias was apparent in one trial, owing 
to the randomisation using an incomplete block 
method.29,32,35,36,38–44 The method of concealment was 
unclear in the remaining trials. Both performance and 
detection biases were evident in a trial conducted by 
Silvers et al. since the investigators were not blinded 
to the patients receiving the intervention.45 Intention-
to-treat analysis was performed in eight trials in order 
to investigate the efficacy of interventions following 
withdrawal of a number of participants.33,37,39,41,43–46 
Patients’ withdrawal had not affected the comparability 
between groups as explored by statistical analyses in 
the remaining trials [Table 2].
traditional medications
Dopamine D2 receptor antagonists
Metoclopramide has dual actions on the brainstem 
and peripheral nerves as a dopamine D2 receptor 
antagonist and serotonin (i.e. 5-HT4) receptor agonist. 
The main effects on the gastrointestinal tract are 
exerted by increasing antral contraction by releasing 
acetylcholine from enteric neurons.47 In DG patients, 
early trials indicated significant improvements in the 
scores of nausea, fullness and bloating after three weeks 
of metoclopramide oral administration as compared to 
the placebo.35,36 In addition, GE improved significantly 
and consistently in all trials of oral regimens assessed 
by GES.34–36 Therefore, it was the sole drug approved 
by the Food and Drug Administration (FDA) for the 
treatment of DG. Rather than oral administration, 
in terms of improving GCSI scores, more recent 
RCTs have shown superior efficacy of nasal spray 
preparations.33,44 However, some AEs were reported 
in other trials, particularly in comparative ones which 
were conducted for more than four weeks.26,33,37 These 
AEs include anxiety, depression, somnolence, headache 
and leg cramps. Furthermore, there are some concerns 
about the development of tardive dyskinesia with the 
chronic use of metoclopramide.48 Diabetes itself may 
be independently associated with the risk of tardive 
dyskinesia.49 Therefore, this medication received a 
‘black box warning’ from the FDA. Collectively, recomm- 
endations indicate the use of metoclopramide for no 
longer than 12 weeks.50
Therefore, alternative medications with high efficacy 
and safety have been studied. Domperidone is another 
dopamine D2 receptor antagonist which is effective 
against nausea and vomiting with a better safety profile 
than metoclopramide. Patterson et al. showed that 
domperidone was associated with less frequent central 
AEs compared to metoclopramide.37 Similarly, dom- 
peridone ameliorated nausea and early satiety compared 
to placebo in adults and cisapride in children with 
DG.25,45 It can be initially administered three times 
daily at a dose of 10 mg, which is increased to 20 mg 
at bedtime. Early prospective investigations conducted 
almost three decades ago revealed that DG symptoms 
improved significantly after six months or one year of 
treatment.51,52 Additionally, it improved the quality of 
life of patients in a subsequent retrospective analysis.53 
However, domperidone may be associated with a risk 
of cardiac arrhythmia and may cause QT prolongation.54 
Therefore, recommendations based on a moderate level 
of evidence indicate performing a baseline electro- 
cardiogram and a cessation of treatment if the corrected 
QT is more than 470 and 450 ms in males and females, 
respectively. Moreover, a follow-up electrocardiogram 
along the course of treatment is advised.55
Ghrelin and ghrelin receptor agonists
Early studies have shown favourable implications of 
ghrelin in the treatment of gastroparesis as it modulates 
energy homeostasis and gastrointestinal motility.27 
This was evident in ten patients with DG using a test 
meal of rice pudding where ghrelin infusion caused a 
significant increase in GE independent of cardiovagal 
tone.27 However, the therapeutic effects of ghrelin 
were limited by its relative plasma instability and short 
half-life.56 Thus, several synthetic ghrelin analogues 
were investigated for their clinical potential. 
TZP-101 (i.e. ulimorelin) is a macrocyclic ghrelin 
receptor analogue which has been investigated in patients 
with DG in a phase 1 trial in Denmark.28 TZP-101 
 
Figure 2: A summary of risk of bias assessment for the included randomised clinical trials (N = 24). 
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Table 2: The outcomes of randomised clinical trials investigating traditional and novel medications for the treatment of diabetic gastroparesis21,25–45,59,66
Author and 
year of study
Study groups and INT Efficacy on gastroparesis symptoms Efficacy on GE Safety
Dopamine D2 receptor antagonist
Snape et al.34 
(1982)
• Metoclopramide (10 mg orally, four 
times per day) 
• Placebo (two 3-week treatment INT with 
a 1-week washout period before cross-over)
• No significant changes observed in 
abdominal pain or bloating
• Using GES, a 24% increase in GE 
rate (P <0.01) was reported 3 weeks 





• Metoclopramide (10 mg orally, four 
times per day) 
• Placebo (for 3 weeks)
• A significant improvement of fullness 
and nausea (P <0.05) in the INT versus 
placebo (assessed using grading diary sheets)
• GE improved in the INT group comp- 
ared to baseline values (P <0.05, assessed 
by GES scintigraphy) but not to placebo
• Restlessness, amenorrhea, headache, 
constipation and leg cramps were noted 




• Metoclopramide (10 mg orally, four 
times per day) 
• Placebo
• Significant improvement of fullness, 
bloating, nausea and anorexia when comp- 
ared to placebo (P <0.05) 
• No significant correlation between changes 
in symptoms and GE improvement
• GE improved significantly (isotope 
retention was 91% at baseline and 
78.6% after metoclopramide admin- 
istration)
• Mild symptoms ignore, such as 
sedation, headache and mild hand 




• Metoclopramide (10 mg orally, four 
times per day; n = 18) 
• Metoclopramide (10 mg nasal spray, 
four times per day; n = 35) 
• Metoclopramide (20 mg nasal spray, 
four times per day; n = 36)
• Using TSS scores, CFB was significantly 
improved in the 20 mg nasal spray group 
compared to the oral group (P = 0.026)
• N/A • Three subjects discontinued the 
study due to severe restlessness, severe 
drowsiness and mild headache. 
• Nausea was more frequently reported 
in the oral group
Parkman et 
al.44 (2015)
• Metoclopramide (10 mg nasal spray, 
four times per day; n = 95) 
• Metoclopramide (14 mg nasal spray, 
four times per day; n = 95) 
• Placebo (n = 95)
• GSDD scores did not improve signific- 
antly in the INT groups as compared to 
placebo 
• Severity scores improved significantly 
only in women for both INT groups as 
compared to placebo (P = 0.02 each)
• N/A • AEs were mild to moderate. They were 
more frequent in the 14 mg (8.4%, incl- 
uding headache, dizziness, diarrhoea, 
cholelithiasis, vomiting and nausea) 
rather than the 10 mg group (nausea, 
myoclonus, and memory impairment)
Patterson et 
al.37 (1999)
The following regimens were given for 
4 weeks: 
• Metoclopramide (one 10 mg tablet 
plus one placebo tablet were taken four 
times per day) 
• Domperidone (two 10 mg tablets 
were taken four times per day)
• No significant differences between 
groups in improving symptoms (improved 
by 41.1% with domperidone and 38.9% 
with metoclopramide)
• N/A • Somnolence, anxiety, akathisia and depr- 
ession were significantly more severe in the 
metoclopramide group after 2 and 4 weeks 
of treatment (P <0.001) 
• Severe CNS events accounted for treatment 
discontinuation in four patients and one 




• Domperidone 20 mg (four times per 
day; n = 105) 
• Placebo (n = 103)
• Significant improvements were noted in the 
domperidone group for total symptoms 
(P = 0.011), nausea (P = 0.024) and early 
satiety (P = 0.004) compared to placebo
• N/A • No significant differences between both 
groups in the tolerability profile 
• Headache, diarrhoea, abdominal pain, 
rhinitis and sinusitis were  most 
commonly reported among patients
Franzese et 
al.25 (2002)
• Domperidone (0.9 mg/kg three times 
per day; n = 14) 
• Cisapride (0.8 mg/kg three times per 
day; n = 14)
• Significant improvements in the TSS in 
both groups (P <0.001 each) compared to 
baseline
• Ultrasonography revealed significant short- 
ening of GE time in the domperidone 
group compared to baseline (P <0.01). 
• No remarkable differences were noted 
in the cisapride group
• N/A
Erbas et al.26 
(1993)
The following regimens were given for 
3 weeks, then 3 weeks washout and 3 
weeks cross-over: 
• Metoclopramide (10 mg orally, three 
times per day) 
• Erythromycin (250 mg orally, three 
times per day)
• The total score of gastrointestinal 
symptoms significantly improved after 
erythromycin (0–5) compared to post-
metoclopramide therapy (0–11; P <0.05)
• Gastric T½ improved significantly in 
both INT groups at 60 and 90 min after 
meal
• Two patients reported sedation, leg 
cramps and weakness, while one patient 





• The patients received either ghrelin 
(5 pmol/kg/min) or saline on two 
different occasions
• No significant differences between ghrelin and 
saline in the incidence of bloating, nausea and 
hunger during infusion as assessed by VAS
• Significant improvement of GE (from 





• A cross-over administration of diff- 
erent doses of TZP-101 infusions 
(80, 160, 320, or 600 g/kg) 
• Placebo
• No significant differences between the 
INT and placebo groups in the intensity 
of post-meal symptoms and postprandial 
fullness
• Gastric T½ (20%; P = 0.043) and 
latency times were significantly 
reduced compared to placebo
• No differences in AEs between TZP-




• A 4-day consecutive regimen of intra- 
venous infusion of ulimorelin at a dosage 
of: 20μg/kg (n = 8); 40μg/kg (n = 17); 
80μg/kg (n = 13); 160μg/kg (n = 6); 
320μg/kg (n = 6); 600μg/kg (n = 7);  
• Placebo (n = 19)
• In the group receiving ulimorelin 80 μg/
kg, the severity of GCSI loss of appetite and 
vomiting scores was significantly improved 
(P = 0.034 and 0.006, respectively) 
• The post-prandial fullness domain of the 
GSA score was significantly improved 
compared to placebo
• No difference in gastric T½ among 
groups
• The frequency and severity of AEs were 





• The following regimens were given 
once daily (oral capsules before break- 
fast) for 28 days: TZP-102 10 mg (n = 22); 
TZP-102 20 mg (n = 21); TZP-102 40 
mg (n = 23); placebo (n = 26)
• All doses (combined) caused a significant 
decline of the GSCI total score compared 
to placebo
• No significant differences in GMBT T½ 
between INT groups and the placebo group 
• No correlation between GMBT T½ 
and the GSCI score at baseline or at 
28 days
• No differences in AEs between the 
TZP-102 and placebo groups
INT = interventions; GE = gastric emptying; GES = gastric emptying scintigraphy; NA = not available; TSS = total symptom score; CFB = change from baseline; CNS = central nervous system; min = min- 
utes; VAS = visual analogue score; AEs = adverse events; GCSI = Gastroparesis Cardinal Symptom Index; GSA = Gastroparesis Symptom Assessment; GMBT = gastric motility breath test; 
GSDD = gastroparesis symptom daily diary; CFB = change from baseline; GEBT = gastric emptying breath test; SC = subcutaneous; DD = daily diary; NVFP = nausea, vomiting, fullness and pain.
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infusion (given at 80, 160, 320, or 600 μg/kg in a cross-
over manner) caused 20% reduction in gastric T½ of 
solids compared to a placebo; however, no apparent 
effects were noted on postprandial symptoms.28 A 
phase 2 trial conducted by the same team revealed that 
the infusion of 80 μg/kg TZP-101 caused a significant 
reduction in severity of several symptoms including 
vomiting, loss of appetite and reduction of the GCSI 
scores (25% versus 8% among patients allocated to 
placebo), although no differences were reported in 
gastric T½.29
Table 2 (contd.): The outcomes of randomised clinical trials investigating traditional and novel medications for the treatment of diabetic gastroparesis21,25–45,59,66
Author and 
year of study
Study groups and INT Efficacy on gastroparesis symptoms Efficacy on GE Safety
McCallum 
et al.43 (2013)
• The following regimens were given 
once per day (oral capsules) for 12 
weeks: TZP-102 10 mg (n = 69); TZP-
102 20 mg (n = 66); Placebo (n = 66)
• GSDD improved significantly in all 
groups, but no difference was reported 
versus placebo (CFB: -1.1 versus 0.98 for 
INT groups and placebo groups)
• No statistical difference in CFB of 
GEBT among all groups
• AEs occurred in 57%, 58% and 67% in 
the 10 mg, 20 mg and placebo groups, 
respectively without remarkable 
differences
Shin et al.38 
(2013)
• Relamorelin 100 μg SC once per day (n = 5) 
• Patients crossed over with a 7-day 
washout period 
• Placebo (n = 5)
• Relamorelin significantly reduced GCSI-
DD (P = 0.041) and NVFP (P = 0.041) 
scores compared to placebo
• GE was significantly accelerated in 
eight patients relative to the placebo 
(P = 0.005)
• No serious AEs were reported 
• Only hunger was almost significant 
with relamorelin use (P = 0.063)
Shin et al.40 
(2013)
• A single dose of relamorelin 100 μg 
SC (n = 5) 
• Patients crossed-over with a 7-day 
washout period 
• Placebo (n = 5) 
• Since it was a single-dose study, it was 
not powered to investigate DG 
• GCSI scores were similar in both groups.
• Gastric T½ of solids, but not liquids, 
reduced by relamorelin versus placebo 
(P = 0.011) 
• Significant effects were noted also in GE 
at 2 and 4 hours (with percent differ- 
ences of 48% and 19%, respectively)




• Relamorelin 10 μg once per day (n = 67) 
• Relamorelin 10 μg twice per day (n = 68) 
• Placebo (n = 69)
• The twice-daily regimen reduced 
vomiting severity and frequency by 60% 
compared to placebo, while it had no 
effects on abdominal pain and satiety
• Significant improvement of GE 
(P <0.03) with twice-daily regimen
• In the INT group ≥5% of patients 




• The following SC injections were 
given twice per day: Relamorelin 100 μg 
(n = 82); Relamorelin 30 μg (n = 109); 
Relamorelin 10 μg (n = 98); Placebo 
(n = 104)
• Relamorelin reduced the frequency of 
vomiting by 75% compared to baseline, but 
not compared to placebo 
• Different doses of relamorelin decreased 
all composite symptoms of DG compared 
to placebo (P <0.05)
• GE was significantly accelerated in 
the 10 and 30 μg groups by 12% 
(P <0.05) compared to placebo after 
12 weeks
• In the INT group, 14.5% of patients 
experienced dose-related deteriorations 





• Erythromycin base 250 mg 
• Erythromycin base 1000 mg 
• Placebo
• N/A • Significant improvements of GE were 
reported between erythromycin groups 
and placebo (P = 0.0007) 
• No differences were present between 
erythromycin 250 and 1000 mg groups
• Diarrhea was reported in one patient in 
the erythromycin 1000 mg group
McCallum 
et al.21 (2007)
• The following regimens were 
given for 12 weeks twice per day: 
Mitemcinal 5 mg (n = 131); Mitemcinal 
10 mg (n = 130); Placebo (n = 131)
• No significant effects were noted over 12 
weeks among groups 
• In a subset of the population under study 
(those having 75% positive weekly responses), 
mitemcinal 10 mg produced a significant imp- 
rovement in total symptoms during the study 
period (P <0.05) compared to placebo
• N/A • Severe AEs were reported in 
18.8%, 15.9% and 20.0% of patients 
in the placebo, mitemcinal 5 mg, and 
mitemcinal 10 mg groups, respectively 
• There were non-significant differences 
among groups
Barton et al.66 
(2014)
• The following regimens were given once 
per day for 4 weeks: Camicinal 10 mg 
(n = 18); Camicinal 50 mg (n = 18); Cami- 
cinal 125 mg (n = 22); Placebo (n = 21)
• The most significant improvements occ- 
urred at 2–4 weeks for fullness and satiety 
for 10 mg (53%) and 50 mg (65%) groups 
• No or little effect was reported for the 
highest dose
• GEBT T½ decreased significantly 
with increasing dose (P <0.05) as 
assessed by swallowed wireless motility 
capsule
• There were similar frequencies of AEs 




• Each patient participated in three 
single oral INT (out of four INT) with 
a 7-day washout period in-between. 
The groups were: Camicinal 50 mg; 
Camicinal 125 mg; Placebo 
• No symptomatic improvement was 
observed
• GEBT T½ decreased by 65% (P <0.05) 
by 125 mg camicinal compared to placebo 
• There was a non-significant trend of 
reduced GEBT T½ with 25 and 50 mg doses 
• A dose-response relationship was apparent
• Headache, vomiting and decreased 
blood glucose were reported in a similar 




• Given thrice per day: Cisapride 
10 mg (n = 9); Placebo (n = 10)
• N/A • GEBT T½ decreased significantly in the 
INT group after 12 months compared 
to baseline (P = 0.03); the placebo 
group showed no changes from baseline 
• No effects were noted on glucose 




• The following treatments were given 
for 3 months, then 4 weeks washout 
and 3 months cross-over: Cisapride 20 
mg twice per day; Placebo
• N/A • GE improved significantly at 120 min 
in the INT group (P = 0.025), while 
gastric T½ did not differ between the 
INT and placebo groups (P = 0.09) 
• No apparent improvements in 
glycaemic control
• No serious AE 
• Patients with prolonged QTc were 
excluded at the initial recruitment phase
INT = interventions; GE = gastric emptying; GES = gastric emptying scintigraphy; NA = not available; TSS = total symptom score; CFB = change from baseline; CNS = central nervous system; min = min- 
utes; VAS = visual analogue score; AEs = adverse events; GCSI = Gastroparesis Cardinal Symptom Index; GSA = Gastroparesis Symptom Assessment; GMBT = gastric motility breath test; 
GSDD = gastroparesis symptom daily diary; CFB = change from baseline; GEBT = gastric emptying breath test; SC = subcutaneous; DD = daily diary; NVFP = nausea, vomiting, fullness and pain.
Pharmacological Approaches to Diabetic Gastroparesis 
A systematic review of randomised clinical trials
e298 | SQU Medical Journal, November 2019, Volume 19, Issue 4
Consequently, TZP-102 was developed as an oral 
preparation. A phase 2a trial was performed in 2013 
to assess the impact of a 28-day TZP-102 regimen 
for doses ranging between 10 and 40 mg versus a 
placebo. Ejskjaer et al. found that all doses (combined) 
significantly alleviated DG symptoms, but with no 
remarkable effects on GE indices.32 Similarly, a phase 
2b trial, which administered TZP-102-CL-G003 and 
TZP-102-CL-G004 for 12 weeks, emphasised the lack 
of improving effects on the Gastroparesis Symptom 
Daily Diary scores as well as GE analysis compared to 
a placebo.43 In addition, the investigations of TZP-102-
CL-G004 were terminated at an early stage due to lack 
of efficacy in DG patients. 
Motilin receptor agonists
Erythromycin has been well-established for its 
prokinetic action since its introduction six decades 
ago.57 Its motilin agonistic action promotes peristaltic 
movement and enhances GE through the induction 
of phase III contractions of the migrating motor 
complex. Thus, it increases gastric antral contraction. 
Early studies revealed that acute intravenous and 
chronic oral administration for four weeks led to a 
significant reduction in the total symptom score in 
DG patients, which may be superior to the effect of 
metoclopramide.26,58 Desautels et al. reported significant 
GE acceleration via a single dose of 250 mg with no 
apparent side effects in diabetic patients.59 However, 
subsequent studies have shown that erythromycin was 
associated with tachyphylaxis, whereby its prokinetic 
effect may be lost after 48 hours of treatment.60 In 
addition, its venous administration may be associated 
with serious AEs such as ventricular arrhythmia and 
can interact with other medications due to inhibition 
of cytochrome P450 C3A4.61,62
Additional medications without antibiotic activities 
and avoiding the previously-mentioned AEs need to 
be developed. Mitemcinal is another motilin agonist 
which has been tested in a 12-week double-blind RCT.46 
Although there was evidence of GE improvements in 
patients with non-delayed GE, the results showed no 
significant differences in the symptoms of DG. 
5-hydroxytryptamine receptor 4 agonists
Cisapride is a traditional non-selective 5-HT4 receptor 
agonist which causes increased muscular contraction 
through cholinergic pathways. Two RCTs have shown 
that the chronic use of this medication (for at least seven 
months) reduces GE time in patients with DG with 
no remarkable effects on their glycaemic control.30,31 
However, both trials excluded patients with prolonged 
QTc at the initial recruitment. Given that cisapride 
administration can activate the Human ether-a-go-
go-related gene (hERG) potassium channels and may 
consequently lead to QT prolongation, ventricular 
arrhythmias and syncope, it has been withdrawn 
from the market in several countries.63 Similarly, the 
use of tegaserod (another 5-HT4 agonist) has been 
suspended since 2007 owing to its association with 
ischaemic cardiovascular events.64 
novel and investigational medications
Ghrelin and ghrelin receptor agonists
RM-131 (i.e. relamorelin), the most recently invest- 
igated member of the ghrelin analogue family, has 
provided promising outcomes. Initially, Shin et al. 
tested the efficacy of subcutaneous injections of RM-
131 in 10 patients with T1DM in a double-blind, 
Table 3: Ongoing clinical trials which investigate candidate medications for diabetic gastroparesis







5-HT4 agonist DG 2 × 2 mg tablets of prucalopride or placebo given 
once daily for 28 days
NCT02031081
Velusetrag (TD-5108) 5-HT4 agonist DG and IG Velusetrag 5, 15, 30 mg capsules once daily versus 
placebo for 12 weeks
NCT02267525
RQ-00000010 5-HT4 agonist Gastroparesis The intervention will be given once daily at doses 
of either 10, 50, 100 μg orally for 2 weeks versus 
placebo
NCT02838797
TAK-906 Dopamine D2 
receptor antagonist
DG and IG TAK-906 5, 25, and 100 mg capsules versus 




DPP-4 inhibitor DG 100 mg sitagliptin once daily for 2 days versus 
placebo
NCT02324010
VLY-686 (Tradipitant) Neurokinin 1 
antagonist
Gastroparesis VLY-686 oral capsule once daily for 4 weeks 
versus placebo
NCT02970968
Relamorelin (RM-131) Selective ghrelin 
receptor agonist
DG Relamorelin 10 μg SC injection twice daily for 12 
weeks versus placebo





5-HT4 = 5-hydroxytryptamine receptor 4; DG = diabetic gastroparesis; IG = idiopathic gastroparesis; DPP-4 = dipeptidyl peptidase-4; SC = subcutaneous.
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cross-over, placebo-controlled RCT and assessed the 
symptoms of DG using the GCSI score and GE using 
scintigraphy.38 Results revealed that gastric T½ was 
significantly accelerated at one and two hours after 
meals compared to a placebo along with significant 
improvements in the average symptoms scores. Similar 
results were reported by Shin et al. in an RCT cond- 
ucted among female patients with T2DM.40 More 
recent data from placebo-controlled RCTs indicated 
that subcutaneous injection of RM-131 twice daily 
had the most remarkable impact on reducing the 
frequency and severity of DG symptoms besides GE 
acceleration.41,42 Additionally, these regimens were safe 
and well-tolerated in all trials. Phase 3 clinical trials are 
on-going concerning this novel medication [Table 3].
Motilin receptor agonists
Camicinal (i.e. GSK962040) is a novel small-molecule 
motilin agonist which causes GE acceleration in healthy 
individuals.65 The pharmacokinetic characteristics of 
camicinal in the latter populations were similar to 
those in patients with T1DM, causing a significant 
reduction of gastric T½ (65% improvement) following 
a single dose of up to 125 mg compared to a placebo 
(52 versus 147 minutes; P <0.05) despite a lack of 
remarkable symptomatic improvements.39 However, 
in a double-blind, phase 2 RCT, Barton et al. found 
a significant amelioration of fullness and early satiety 
after camicinal administration (10 and 50 mg) for four 
weeks.66
5-hydroxytryptamine receptor 4 agonists
There are multiple on-going investigations concerning 
new 5-HT4 receptor agonists that exert beneficial 
outcomes on the gastrointestinal tract without prom- 
inent AEs on cardiac muscle. However, these trials are 
either performed on patients with idiopathic gastro- 
paresis or their outcomes have not been published 
yet. Revexepride is a specific agonist that has been 
tested in an RCT on diabetic and non-diabetic 
patients with gastroparesis.22 There were no significant 
improvements in GCSI scores, GE or quality of life of 
patients allocated to the intervention group versus a 
placebo.22 Prucalopride is a selective 5-HT4 agonist 
which significantly reduced GEBT T½ compared to a 
placebo (P <0.050) as well as GSCI scores of bloating/
distension (P <0.001), nausea/vomiting (P = 0.010) 
and fullness (P <0.001) when it was given at a dose of 
2 mg once a day for four weeks.67 A phase 2 trial in 
DG patients was completed with no reported results 
so far [Table 3]. Likewise, velusetrag, which has been 
proven for its GE-accelerating effects in patients with 
constipation, is being investigated in patients with 
gastroparesis.
Discussion
DG is a relatively common complication among 
diabetic patients. Nevertheless, there is no consensus 
on the optimal management approach. Hence, several 
medications have been tested to relieve the symptoms 
in individuals with an established health burden. 
The current article aimed to review the best level of 
evidence, namely RCTs, which tested the efficacy and 
safety of medications targeting DG. Results showed 
multiple safety concerns of the currently used drugs. 
While metoclopramide is the only FDA-approved 
drug, other traditional drugs have been withdrawn 
from the markets of several countries owing to risky 
complications, mostly cardiovascular, in diabetic patients. 
Current efforts are aimed at developing novel medic- 
ations and/or new safe preparations of traditional drugs.
Metoclopramide can interfere with emesis through 
its action on the central nervous system and increase 
gut motility via its prokinetic effect. Due to the 
risk of AEs such as tardive dyskinesia, it has been 
traditionally prescribed at the lowest effective dose 
for short periods of time. The novel intranasal 
preparation is seemingly more practical due to the 
intolerability of oral medications in DG patients with 
severe nausea and vomiting. For those who are unable 
to use metoclopramide, domperidone has recently 
been granted FDA’s expanded access investigational 
new drug application in adults with gastroparesis.68 
This drug should be prescribed to manage severe 
symptoms in patients whom the potential benefits 
of the medication may justify its potential risks. 
Although the impact on the central nervous system 
is not apparent, domperidone still has cardiovascular 
risks owing to its tendency of causing a prolonged 
QTc interval. Seemingly, intravenous erythromycin is 
warranted in hospitalised patients who need intra- 
venous therapy as they are continually monitored for 
any AEs.69
Recent trials showed promising effects of the 
novel ghrelin receptor agonist relamorelin, the motilin 
receptor agonist camicinal and the 5-HT4 agonist 
prucalopride. Subcutaneous relamorelin has been 
effective and safe in healthy individuals and in DG 
patients has been shown to accelerate GE and induce 
antral contraction.42,70 The most effective doses are 10 
and 20 µg while the on-going RCTs use the smaller 
dose to assess its efficacy in managing gastroparesis 
symptoms. Camicinal can be considered an attractive 
candidate for the treatment of DG as it showed GE 
acceleration in a dose-dependent manner in healthy 
and diabetic patients at a minimum dose of 125 mg.39,71 
Owing to small sample sizes and its administration at a 
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single dose, the conducted RCTs failed to demonstrate 
significant effects on DG symptoms. As such, further 
trials are warranted giving due consideration to using 
multiple-dose regimens and recruiting larger samples. 
Prucalopride is approved in many countries for the 
treatment of chronic constipation and its preliminary 
favourable actions on patients with gastroparesis may 
be attributable to its high affinity to 5-HT4 receptors 
with no effects on hERG channels.67,72
The efficacy of prokinetics in diabetic patients 
may be affected by other factors which can decrease 
GE. For instance, the patient’s diabetologist should be 
consulted regarding the use of GLP-1 analogues such as 
liraglutide and exenatide as well as incretin-based drugs 
(e.g. pramlintide) as they may interfere with GE.73,74 
Furthermore, while there is no confirmative evidence 
of the relationship between long-term improved 
glycaemic control, the symptoms of DG and the rates 
of GE, studies have shown that acute hyperglycaemia 
can slow GE in diabetic patients.75,76 It is worth noting 
that a diet rich in both fibre and fat can delay GE. As 
such, the main essence of dietary interventions should 
be consuming small and frequent meals which are 
low in fat and fibre.50,77 Additionally, a recent RCT 
has indicated the significance of small-particle size 
diets in reducing the severity of key symptoms of DG 
including postprandial fullness, nausea/vomiting and 
bloating.78
Ethnic-based differences in disease presentation 
have been reported in a retrospective analysis of adult 
patients in the National Institutes of Health Gastroparesis 
Consortium registries, where non-Hispanic blacks 
with DG had more severe symptoms (nausea/vomiting) 
and more frequent hospitalisation rates compared to 
non-Hispanic whites.79 The increased severity of DG 
symptoms in non-whites was also reported in other 
cross-sectional studies.80,81 Additionally, Hispanics were 
more likely to develop gastroparesis secondary to diabetes 
than non-Hispanic whites who experienced idiopathic 
gastroparesis.79 Therefore, domperidone treatment and 
peripherally inserted catheters were less used in Hispanics 
compared to non-Hispanic whites. Nonetheless, the 
therapeutic effects based on racial differences were not 
exclusively investigated in RCTs. Studies employing 
a large proportion of white patients of Caucasian 
heritage (>80%) showed acceptable efficacy and safety 
outcomes after using ulimorelin, relamorelin and 
domperidone.29,41,45
The use of antiemetics predominantly focuses on 
symptomatic management. Antihistamines (i.e. prome- 
thazine) and phenothiazines (i.e. prochlorperazine) 
are frequently prescribed, yet they may interact with 
the prokinetics particularly if the medications are 
metabolised through the CYP450 pathway. Serotonin 
5-HT3 receptor antagonists, such as ondansetron and 
dolasetron, may be used in emergency settings when 
other therapies fail to relieve nausea; little is known 
about their efficacy in gastroparesis secondary to 
diabetes.82 Moreover, patients with profound nausea 
and vomiting may benefit from synthetic cannabinoids, 
including dronabinol and nabinol, although they 
showed variable pharmacokinetic profiles.83 They may 
be associated with a risk of hyperemesis on withdrawal 
and were not previously tested in DG patients.84
Recently, aprepitant, a neurokinin 1 (NK-1) receptor 
antagonist, has shown encouraging outcomes. While 
it was originally used for managing chemotherapy-
induced nausea and vomiting, a 4-week, double-blind 
multicentre trial revealed that aprepitant ameliorated 
the severity of nausea, vomiting and all GCSI symptoms 
in patients with all-cause gastroparesis.85,86 Moreover, 
Fountoulakis et al. found that this medication was 
effective in the long-term management of severe 
symptoms in two cases of DG refractory to treatment 
with first-line medications.87 Currently, the efficacy 
of a 4-week regimen of tradipitant, another NK-1 
receptor antagonist, is being investigated to manage 
gastroparesis. 
This review provides an updated overview of 
the currently used medications and their therapeutic 
effects on patients with gastroparesis secondary to 
diabetes in RCTs. Other systematic reviews have 
summarised pharmacological and other management 
approaches to DG, such as nutritional support, glycaemic 
management, surgical techniques, intrapyloric botulinum 
toxin injection and gastric electrical stimulation. 
However, the current review was subject to 
some limitations. The impact of antiemetics was not 
assessed due to a lack of relevant RCTs. Furthermore, 
the design of included RCTs might have impacted the 
results. For example, there were conflicting outcomes 
between phase 2a and phase 2b studies of TZP-102 
which included variations in breath test methods (a 
6-hour 13C-octanoate test and a 3-hour 13C-Spirulina 
platensis test, respectively).32,43 Therefore, unified guide- 
lines should be implemented and carefully employed 
for future trials. The FDA has provided several 
recommendations regarding this aspect, which include 
conducting double-blind, placebo-controlled trials with 
a 2-week screening period, a 12-week treatment period 
and an at least 2-week withdrawal period.88 RCTs of 
longer durations should be performed for at least 
12 months. Importantly, patients with diabetic and 
idiopathic gastroparesis should be studied in separate 
trials. Finally, efficacy assessment should primarily be 
based on the signs and symptoms of gastroparesis.
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Conclusion 
There is a significant unmet need for patients with 
DG who require effective medications to manage their 
symptoms with optimal levels of safety. Patients with 
mild to moderate symptoms are traditionally managed 
with metoclopramide or domperidone taking into 
consideration their cardiovascular consequences. In an 
endeavour to develop novel drugs, relamorelin, camicinal 
and prucalopride have shown the best outcomes; 
however, further investigations are required prior to 
approval for use in a healthcare setting. Future trials 
should be conducted based on unified guidelines such 
as those implemented by the FDA in order to enable 
comprehensive and reliable assessment of their outcomes. 
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